Medium-dose intravenous immunoglobulin therapy for women with six or more recurrent miscarriages

J Reprod Immunol. 2015 Jun:109:48-51. doi: 10.1016/j.jri.2015.01.008. Epub 2015 Feb 20.


This study aimed to evaluate changes in natural killer (NK) cell activity and the percentage of monocytes in women with recurrent miscarriage who received medium-dose intravenous immunoglobulin (IVIg) therapy. Fourteen women with a history of six or more recurrent miscarriages of unexplained etiology received 60-g IVIg therapy (20 g daily, for three days) during early gestation. NK cell activity in the peripheral blood decreased to 12% one week after therapy compared with before therapy (median, 22%, P < 0.001) and the percentage of monocytes increased from 5.2% to 7.5% (P < 0.005). Four pregnancies ended in live births of healthy neonates, whereas the other ten pregnancies ended in miscarriages. Excluding one miscarriage with a chromosomal abnormality, the live birth rate was 30.8% (4/13). The rate of reduction of NK cell activity in the success group (-58.8%) tended to be greater than that in the failure group (-14.8%, P = 0.057).

Keywords: Etiology; Immunoglobulin; Recurrent miscarriage.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Spontaneous* / blood
  • Abortion, Spontaneous* / drug therapy
  • Abortion, Spontaneous* / immunology
  • Adult
  • Female
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / metabolism
  • Lymphocyte Count
  • Parturition
  • Pregnancy


  • Immunoglobulins, Intravenous